ProCE Banner Activity

Optimizing Immune Checkpoint Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer

Podcast Episodes

Learn from a leading expert about optimizing immune checkpoint inhibitors in advanced non-small-cell lung cancer (NSCLC) including individualizing therapy decisions and managing adverse events.

Released: June 30, 2022

Expiration: June 29, 2023



Sandip P. Patel

Sandip P. Patel, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California San Diego
San Diego, California


This activity is supported by educational grants from Bristol Myers Squibb; Genentech, a member of the Roche Group; Merck Sharp & Dohme Corp.; and Regeneron Pharmaceuticals, Inc and Sanofi.

Provided by

ProCE Banner


Bristol Myers Squibb

Genentech, a member of the Roche Group

Regeneron Pharmaceuticals, Inc


Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify currently approved ICIs and the role of biomarker testing in their use in advanced NSCLC

  • Describe recommended, evidence-based strategies to individualize treatment with ICIs for patients with advanced NSCLC

  • Implement effective strategies for identification and management of irAEs in patients treated with ICIs


Sandip P. Patel, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Genentech, Illumina, Merck, Pfizer, and Rakuten Medical; researcher: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Iovance Biotherapeutics, Merck, Pfizer.




The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.